Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Observational Study Evaluating Effectiveness and Safety of Real-World Treatment With Damoctocog Alfa Pegol in Previously Treated Patients With Hemophilia A

Trial Profile

Observational Study Evaluating Effectiveness and Safety of Real-World Treatment With Damoctocog Alfa Pegol in Previously Treated Patients With Hemophilia A

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Damoctocog alfa pegol (Primary)
  • Indications Haemophilia A
  • Focus Therapeutic Use
  • Acronyms HEM-POWR
  • Sponsors Bayer

Most Recent Events

  • 14 Mar 2024 Status changed from recruiting to active, no longer recruiting.
  • 13 Dec 2022 Results of post hoc analysis of this trial to explore the safety and effectiveness of extended dosing with damoctocog alfa pegol presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 09 Nov 2022 Results of post-hoc subgroup analysis (n=31; data cut-off 31 August 2021) assessing effectiveness and safety of damoctocog alfa pegol utilisation during routine clinical practice, presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top